Novo Nordisk: Oddo BHF raises TP
(CercleFinance.com) - Oddo BHF maintains its "outperform" rating on Novo Nordisk shares, raising its target price for them from 720 DKK to 800 DKK.
The analyst reports that Novo Nordisk's management has announced another hike to its 2023 guidance (the third since the start of the year), due to more ambitious sales prospects for 2023 than initially forecast.
Sales are now expected to rise by between 32% and 38% (cer), with EBIT growth of 40% to 46%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The analyst reports that Novo Nordisk's management has announced another hike to its 2023 guidance (the third since the start of the year), due to more ambitious sales prospects for 2023 than initially forecast.
Sales are now expected to rise by between 32% and 38% (cer), with EBIT growth of 40% to 46%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.